Isocavernane diterpenoid compound, pharmaceutical composition thereof, preparation method and application of isocavernane diterpenoid compound
The isospongean diterpene compound 3-epi-kravanhin A extracted and prepared from the stems and leaves of the grass fruit, solved the problem of side effects of existing blood sugar-lowering drugs, achieved significant blood sugar-lowering and weight loss effects, and provided new and multi-dimensional Target drugs and health food solutions.
Patent Information
- Application Number
- CN202410946364.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-16
Smart Images

Figure CN118909025A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of pharmaceutical technology, and in particular to an isosponge diterpene compound, a pharmaceutical composition thereof, a preparation method thereof and an application thereof. Background Art
[0002] Type 2 diabetes mellitus (T2DM) is a chronic disease caused by insulin resistance or insufficient insulin secretion, which leads to increased blood sugar levels. Due to long-term high blood sugar, type 2 diabetes often leads to serious complications such as retinopathy, nephropathy, hypertension, etc.
[0003] Currently, there are a variety of oral hypoglycemic drugs on the market, including biguanides, α-glucosidase inhibitors, insulin secretagogues, insulin sensitizers, glucagon-like peptide-1 (GLP-1) receptor agonists, dipeptidyl peptidase-4 (DPP4) inhibitors and sodium-glucose cotransporter-2 (SGLT-2) inhibitors, etc. However, the side effects of the above-mentioned oral hypoglycemic drugs, such as acute hypoglycemia, weight gain, gastrointestinal discomfort and hepatotoxicity, limit their application.
[0004] Tsaoko is an important spice in my country and is often used in traditional Chinese medicine to treat abdominal distension, vomiting, malaria and other diseases. Previous studies have isolated various types of compounds such as diarylheptanes, flavonoids, and monoterpenes from tsaoko, some of which have antiemetic, antiasthmatic, anti-gastric ulcer, anti-proliferative, antiviral, antioxidant, anti-inflammatory, and antibacterial biological activities.
[0005] At present, there are no reports on the extraction of active substances from Amomum villosum to prepare blood sugar-lowering or weight-loss drugs or health foods in existing research; therefore, how to extract active substances from Amomum villosum to prepare blood sugar-lowering or weight-loss drugs or health foods is a technical problem that technicians in this field urgently need to solve.
[0006] The information disclosed in this background technology section is only intended to enhance the understanding of the overall background of the invention and should not be regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art. Summary of the invention
[0007] In view of the above technical problems, the embodiments of the present invention provide an isosponge diterpene compound, a pharmaceutical composition thereof, a preparation method thereof and an application thereof to solve the problems raised in the above background technology.
[0008] An isospongane diterpene compound, characterized in that its structural formula is as shown in formula (I): This isospongane diterpene compound is named: 3-epi-kravanhinA;
[0009]
[0010] A use of the isosponge diterpene compound as described above in the preparation of a GLP-1 secretagogue drug.
[0011] A use of the isosponge diterpene compound as described above in the preparation of DPP-4 inhibitor drugs.
[0012] A use of the isosponge diterpene compound as described above in the preparation of hypoglycemic drugs or weight-loss drugs.
[0013] An application of the isosponge diterpene compound as described above in the preparation of health food; the health food has the function of lowering blood sugar or losing weight.
[0014] A pharmaceutical composition, wherein the active ingredient of the pharmaceutical composition comprises the isosponge diterpene compound or a pharmaceutically acceptable salt thereof as described in claim 1.
[0015] Preferably, it also includes at least one of a pharmaceutically acceptable carrier, excipient, adjuvant and vehicle.
[0016] A use of the above-mentioned pharmaceutical composition in the preparation of a hypoglycemic drug or a weight-loss drug or a health food with the function of hypoglycemic and weight-loss.
[0017] A method for extracting isosponge diterpenoid compounds as described above, wherein the isosponge diterpenoid compounds are extracted from the stems and leaves of Amomum villosum.
[0018] Preferably, the extraction method specifically comprises the following steps:
[0019] The stems and leaves of Amomum villosum were crushed, and refluxed and extracted twice with 70% ethanol at room temperature, each time for 48 hours, and the ethanol extracts were combined;
[0020] The combined ethanol extracts are recovered under reduced pressure to obtain an extract, the extract is dispersed in water and extracted with ethyl acetate, and concentrated to obtain an ethyl acetate extract;
[0021] The ethyl acetate extraction part was subjected to silica gel column chromatography, and gradient elution was performed with acetone-petroleum ether in volume ratios of 0:100, 2:98, 5:95, 10:90, 20:80 and 100:0, respectively, and multiple primary fractions obtained after elution were eluted with ethyl acetate-petroleum ether in a volume ratio of 10:90-80:20 to obtain secondary fractions, and the secondary fractions were detected by TLC and the same fractions were combined;
[0022] The secondary fractions after merging the same fractions were eluted with methanol-water in a volume ratio of 20:80-100:0 to obtain a tertiary fraction; the obtained tertiary fraction was purified by HPLC, eluted with acetonitrile-water to obtain a quaternary fraction, and the quaternary fraction was qualitatively screened to obtain isosponge diterpene compounds.
[0023] An isosponge diterpene compound, a pharmaceutical composition thereof, a preparation method thereof, and an application thereof provided in an embodiment of the present invention have the following beneficial effects:
[0024] 1. The present invention extracts the isosponge diterpene compound 3-epi-kravanhin A from the stems and leaves of Amomum villosum for the first time, and the compound structure of the isosponge diterpene is a new compound reported for the first time;
[0025] 2. The present invention isolates the isosponge diterpene compound 3-epi-kravanhin A from the stems and leaves of Amomum villosum, which has obvious GLP-1 secretion promotion and DPP-4 inhibition activities, indicating that the compound 3-epi-kravanhin A has blood sugar lowering and weight loss effects;
[0026] 3. The compound 3-epi-kravanhin A of the present invention has both the activity of promoting GLP-1 secretion and inhibiting DPP-4, and is a novel multi-target active molecule for lowering blood sugar and reducing weight;
[0027] 4. The preparation method of the present invention is simple and easy to operate, uses discarded stems and leaves of Amomum villosum as raw materials, has low cost, is environmentally friendly and safe, and has high feasibility. BRIEF DESCRIPTION OF THE DRAWINGS
[0028] Figure 1 . is a schematic diagram of the structural formula of the compound 3-epi-kravanhin A of the present invention;
[0029] Figure 2 The dose-effect relationship of the compound 3-epi-kravanhin A of the present invention in promoting GLP-1 secretion;
[0030] Among them, bile acid (CA) was used as a positive control; *P<0.05, **P<0.01, ***P<0.001 relative to the control group; the values are expressed as mean±standard deviation (n=3). DETAILED DESCRIPTION
[0031] The technical solutions in the embodiments of the present invention are described clearly and completely below. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, all other embodiments obtained by those skilled in the art without creative work are within the scope of protection of the present invention.
[0032] In view of the above technical problems, the embodiments of the present invention provide an isosponge diterpene compound, a pharmaceutical composition thereof, a preparation method thereof and an application thereof to solve the problems raised in the above background technology.
[0033] Embodiment 1:
[0034] 1. Preparation of compound 3-epi-kravanhin A:
[0035] The stems and leaves of Amomum villosum were crushed and extracted twice with 70% ethanol at room temperature for 48 hours each time. The ethanol extracts were combined and the ethanol was recovered under reduced pressure to obtain an extract. The extract was dispersed in water and extracted with ethyl acetate. The extract was concentrated to obtain the ethyl acetate extract. The ethyl acetate extract was then chromatographed on a silica gel column using acetone-petroleum ether (0:100, 2:98, 5:95, 10:90, 20:80 and 100:0, v / v) as the eluent for gradient elution to obtain 10 fractions. Fraction Fr.8 was chromatographed on a silica gel column using ethyl acetate-petroleum ether (10:90-80:20) as the eluent. The same fractions were combined by TLC detection to obtain Fr.8-1-Fr.8-6. Fr.8-4 was subjected to MCI CHP20P (methanol-water, 20:80-100:0) column chromatography gave Fr.8-4-1-Fr.8-4-4; Fr.8-4-1 was purified by HPLC (Rp-C8 column) and eluted with acetonitrile-water (39:61) to give compound 3-epi-kravanhin A.
[0036] It should be noted that the fraction Fr.8 obtained by gradient elution is subjected to silica gel column chromatography to obtain Fr.8-1-Fr.8-6, and then fraction Fr.8-4 is selected from Fr.8-1-Fr.8-6 for column chromatography to obtain Fr.8-4-1-Fr.8-4-4, and then fraction Fr.8-4-1 is selected from Fr.8-4-1-Fr.8-4-4 for purification and elution to obtain the target substance. This is a process of reverse experimental methods. After research, we found that the target molecule obtained from fraction Fr.8-4-1 has the target activity. Therefore, fraction Fr.8-4-1 was taken as the final target substance, the screening and extraction method was traced back, and the separation and acquisition method of the target substance was directly given.
[0037] 2. Structural data of compound 3-epi-kravanhin A:
[0038] The optical rotation was measured by a Jasco model 1020 polarimeter (Horiba, Tokyo, Japan). The infrared spectrum (IR) was measured by a Bio-Rad FTS-135 infrared spectrometer (Hercules, California, USA) using the KBr pellet method. The UV spectrum was measured by a UV-2401PC UV spectrometer (Shimadzu, Kyoto, Japan). ECD spectra were measured by Applied Photophysics circular dichroism spectrometer (Agilent, Santa Clara, United States); nuclear magnetic resonance spectra (1D and 2D NMR) were measured by AV800 or Avance III-600 superconducting nuclear magnetic resonance spectrometer (Bruker, Bremerhaven, Germany), using deuterated chloroform as solvent; high-resolution mass spectrometry (HRMS) was measured by LCMS-IT-TOF mass spectrometer (Shimadzu, Kyoto, Japan); thin layer chromatography silica gel and column chromatography silica gel (200-300 mesh) were purchased from Qingdao Meigao and Qingdao Ocean Chemical Group Co., Ltd., and Sephadex LH-20 was purchased from Amersham Bioscience (Sweden). CHP20PMCI gel was purchased from Mitsubishi Chemical Corporation (Tokyo, Japan).
[0039] The structural data of DeoxycalyxinA are as follows: isosponge diterpene compound, named 3-epi-kravanhinA; molecular formula: C 20 H 28 O4,; molecular weight: 332; properties: white needle-shaped crystals; HRESIMS m / z 355.1880 ([M+Na] + ,calcd.forC 20 H 28 O4, 355.1880, 0.0 mDa); UV(MeOH)λ max (logε):217(3.02)nm; 1 HNMR and 13 CNMR (DEPT) data are shown in Table 1.
[0040] Table 1. Compounds 3-epi-kravanhinA 13 C(150MHz) and 1 HNMR (600 MHz, Jin Hz) data, the test solvent is CDCl3 (δin ppm, Jin Hz).
[0041]
[0042] Embodiment 2:
[0043] GLP-1 secretion promoting activity and DPP-4 inhibitory activity of the compounds
[0044] 1. Materials and Methods
[0045] 1.1. Materials
[0046] STC-1 cells were purchased from the ATCC cell bank in the United States; DMEM medium and RPMI-1640 medium were purchased from Vivacell, Italy; F12 medium and F12K medium were purchased from Thermo Fisher Scientific, USA; protease inhibitor cocktail was purchased from Shanghai Biotech Co., Ltd., China; fatty acid-free bovine serum albumin was purchased from Shanghai Liji Biotechnology Co., Ltd.; Matrigel matrix glue was purchased from Becton, Dickinson and Company, USA; and the mouse GLP-1 kit was purchased from Wuhan Huamei Bioengineering Co., Ltd.
[0047] 1.2. Instruments
[0048] Flex Station 3 multifunctional microplate reader was purchased from Bio-Rad Laboratories; FlexA-200 full-wavelength microplate analyzer was purchased from Hangzhou Aosheng Instrument Co., Ltd.; analytical balance ME104E was purchased from Mettler-Toledo Instrument (Shanghai) Co., Ltd.; electric constant temperature incubator (DHP-9082) was purchased from Shanghai Yiheng Technology Co., Ltd. Cell constant temperature incubator was purchased from Singapore esco Technology Co., Ltd.; inverted fluorescence microscope was purchased from Olympus, Japan; fluorescence and chemiluminescence imaging analysis system was purchased from Beijing Saizhi Venture Technology Co., Ltd., China.
[0049] 1.3 Experimental procedures
[0050] GLP-1 secretion experiment: STC-1 cells were cultured in DMEM medium containing 10% FBS and 1% PS at 37°C and 5% CO2 saturated humidity incubator; when the cells grew to 80%-90%, the diluted cell suspension was inoculated into a 24-well plate (5×10 5 Each well was starved for 1 hour after adding KRBH; each well was starved for 2 hours after adding KRBH working solution containing compound, and the supernatant was collected; the GLP-1 content in the supernatant was detected using mouse GLP-1 ELISA kit.
[0051] DPP-4 activity screening: Working buffer (Tris-HCl) is prepared by dissolving 605.6 mg of Tris and 28.5 mL of 0.118 mol / L hydrochloric acid solution in 100 mL of ultrapure water after adjusting pH=8.0. Glycylproline p-nitroanilide (GLY-PRO-PNA 25 mg) dissolved in 7.6 mL of Tris-HCl is used as substrate. 420 mg of NaHCO3 is dissolved in 50 ml of ultrapure water as NaHCO3 stop solution. 70 μL of Tris-HCl, 10 μL of the sample to be tested dissolved in DMSO and 10 μL of PTP1B enzyme (5 mg / L) are added to a 96-well plate in sequence. After incubation at 37°C for 10 min, the reaction is initiated by adding 10 μL of substrate, followed by incubation for 30 min. 100 μL of Na2CO3 solution is added to the reaction mixture to terminate the reaction, and the absorbance is measured at 405 nm using an ELISA reader, and the results are recorded. The negative control used DMSO instead of the test solution, the positive control was sitagliptin, and the other methods were the same. The DPP-4 inhibition rate was calculated as inhibition rate (%) = (△ enzyme - △ sample / △ enzyme - △ negative) × 100%. The experimental results were analyzed using Graphpad prism 8.0 software.
[0052] 2. Results:
[0053] 2.1. GLP-1 secretion activity:
[0054] The isospongane diterpene compound disclosed in the present invention is isolated from the stems and leaves of Amomum villosum for the first time, and the compound 3-epi-kravanhinA acts on STC-1 cells to evaluate its effect on the secretion of GLP-1. As shown in Table 2, the compound 3-epi-kravanhinA can significantly promote the secretion of GLP-1 at 60 μM, and the secretion promotion rate is 109.7%.
[0055] Further study of the dose-effect relationship at concentrations of 5-160 μM (see Figure 2 ), compound 3-epi-kravanhinA was able to promote the secretion of GLP-1 in a dose-dependent manner without affecting cell survival, indicating that 3-epi-kravanhinA has significant GLP-1 secretion-promoting activity.
[0056] Table 2. Effect of compound 3-epi-kravanhinA on the secretion of GLP-1 in STC-1 cells (60 μM) a .
[0057]
[0058] a Values are expressed as mean ± standard deviation (n = 3); bThe secretion promotion rate indicated the percentage increase of GLP-1 content compared with the control group; c Bile acid was used as a positive control.
[0059] 2.2.DPP-4 inhibitory activity:
[0060] Endogenous GLP-1 is unstable in the body and is rapidly degraded by the DPP-4 enzyme. Therefore, DPP-4 inhibitors are effective drugs for increasing endogenous GLP-1 in the human body. This study further evaluated the inhibitory effect of compound 3-epi-kravanhinA on the DPP-4 enzyme (see Table 3). Compound 3-epi-kravanhinA had a moderate inhibitory effect on the DPP-4 enzyme at concentrations of 200 and 400 μM, with inhibition rates of 31.0% and 46.5%, respectively.
[0061] Table 3. Inhibitory activity of compound 3-epi-kravanhinA against DPP-4 a .
[0062]
[0063] a The inhibitory effects are expressed as mean ± SD (n = 3); sitagliptin was used as a positive control.
[0064] It should be noted that GLP-1 and DPP-4 are biological molecules related to insulin regulation and blood sugar control: GLP-1 is an insulin secretogen before insulin secretion, which can promote insulin secretion, improve insulin sensitivity, reduce insulin decomposition and inhibit glucagon secretion, and can act on the central nervous system to reduce appetite and increase satiety;
[0065] DPP-4 is an enzyme present in multiple cell types whose main function is to degrade glucagon and GLP-1; by degrading GLP-1, DPP-4 can reduce the biological activity and half-life of GLP-1, thereby regulating insulin secretion and blood glucose levels.
[0066] 3. Conclusion:
[0067] The present invention separates a new isosponge diterpene 3-epi-kravanhinA from the stems and leaves of Amomum villosum for the first time, which can significantly promote the secretion of GLP-1 at 60 μM and present a dose-dependent relationship. At the same time, it has a moderate inhibitory effect on the DPP-4 enzyme at a concentration of 200 and 400 μM. Therefore, 3-epi-kravanhin A has both GLP-1 secretion promoting activity and DPP4 inhibitory activity, and has obvious advantages over existing single-target drugs (such as GLP-1 agonists or DPP4 inhibitors) on the market, and has great potential for development into hypoglycemic and weight-loss drugs, and can be used in hypoglycemic and weight-loss drugs and health foods.
[0068] Embodiment 3:
[0069] Preparation Example:
[0070] Take compound 3-epi-kravanhin A, dissolve it with a small amount of DMSO, add water for injection, filter it, and sterilize it to make an injection solution;
[0071] Take compound 3-epi-kravanhin A, dissolve it with a small amount of DMSO, dissolve it in sterile water for injection, stir to dissolve, filter it with a sterile suction filter funnel, filter it with sterile fine filtration, pack it into ampoules, freeze-dry it at low temperature, and aseptically seal it to obtain a powder injection;
[0072] Compound 3-epi-kravanhin A was taken and excipients were added in a weight ratio of 9:1 to the excipients to prepare a powder;
[0073] Compound 3-epi-kravanhin A was taken, excipients were added in a weight ratio of 5:1, granulated and tableted;
[0074] Take compound 3-epi-kravanhin A and prepare it into oral solution according to the conventional oral solution preparation method;
[0075] Compound 3-epi-kravanhin A was taken and excipients were added in a weight ratio of 5:1 to the excipients to prepare capsules;
[0076] Compound 3-epi-kravanhin A was taken and excipients were added in a weight ratio of 3:1 to the excipients to prepare capsules;
[0077] The compound 3-epi-kravanhin A was taken and excipients were added in a weight ratio of 5:1 to the excipients to prepare granules.
[0078] The embodiments described above are only descriptions of the preferred implementation modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should fall within the protection scope determined by the claims of the present invention.
Claims
1. An isosponge diterpene compound, characterized in that: Its structural formula is shown in formula (I):
2. Use of the isosponge diterpene compound as claimed in claim 1 in the preparation of a GLP-1 secretagogue drug.
3. Use of the isosponge diterpene compound as claimed in claim 1 in the preparation of DPP-4 inhibitor drugs.
4. Use of the isosponge diterpene compound as claimed in claim 1 in the preparation of hypoglycemic drugs or weight loss drugs.
5. A use of the isosponge diterpene compound according to claim 1 in preparing health food; characterized in that: The health food has the function of lowering blood sugar or losing weight.
6. A pharmaceutical composition, characterized in that The active ingredient in the pharmaceutical composition comprises the isosponge diterpene compound or a pharmaceutically acceptable salt thereof as claimed in claim 1.
7. The pharmaceutical composition according to claim 6, characterized in that It also includes at least one of a pharmaceutically acceptable carrier, excipient, adjuvant and vehicle.
8. Use of the pharmaceutical composition according to claim 6 or 7 in the preparation of hypoglycemic drugs or weight-loss drugs or health foods with hypoglycemic and weight-loss functions.
9. A method for extracting isosponge diterpene compounds as claimed in claim 1, characterized in that: The isosponge diterpene compound is extracted from the stems and leaves of Amomum villosum.
10. The method for extracting isosponge diterpene compounds according to claim 9, characterized in that: The extraction method comprises the following steps: The stems and leaves of Amomum villosum were crushed, and refluxed and extracted twice with 70% ethanol at room temperature, each time for 48 hours, and the ethanol extracts were combined; The combined ethanol extracts are recovered under reduced pressure to obtain an extract, the extract is dispersed in water and extracted with ethyl acetate, and concentrated to obtain an ethyl acetate extract; The ethyl acetate extraction part was subjected to silica gel column chromatography, and gradient elution was performed with acetone-petroleum ether in volume ratios of 0:100, 2:98, 5:95, 10:90, 20:80 and 100:0, respectively, and multiple primary fractions obtained after elution were eluted with ethyl acetate-petroleum ether in a volume ratio of 10:90-80:20 to obtain secondary fractions, and the secondary fractions were detected by TLC and the same fractions were combined; The secondary fractions after merging the same fractions were eluted with methanol-water in a volume ratio of 20:80-100:0 to obtain a tertiary fraction; the obtained tertiary fraction was purified by HPLC, eluted with acetonitrile-water to obtain a quaternary fraction, and the quaternary fraction was qualitatively screened to obtain isosponge diterpene compounds.
